Literature DB >> 16134933

The first de novo-designed antagonists of the human NK(2) receptor.

Mohammed A Ali1, Nirmala Bhogal, John B C Findlay, Colin W G Fishwick.   

Abstract

The de novo molecular design program SPROUT has been used in conjunction with a molecular model to produce a molecular template for a new class of NK(2) receptor antagonist. An efficient, stereocontrolled synthesis of a small series of molecules, designed to test the validity of this template, was developed. Competition assays using recombinant human NK(2) receptor support the structural requirements of this new designed molecular template.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16134933     DOI： 10.1021/jm050533o

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  6 in total

1.  A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.

Authors:  J Kankanala; A M Latham; A P Johnson; S Homer-Vanniasinkam; C W G Fishwick; S Ponnambalam
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Catalytic Enantioselective Intermolecular [5 + 2] Dipolar Cycloadditions of a 3-Hydroxy-4-pyrone-Derived Oxidopyrylium Ylide.

Authors:  Katherine N Fuhr; Danielle R Hirsch; Ryan P Murelli; Stacey E Brenner-Moyer
Journal:  Org Lett       Date:  2017-11-17       Impact factor: 6.005

3.  Catalytic asymmetric synthesis of 8-oxabicyclooctanes by intermolecular [5+2] pyrylium cycloadditions.

Authors:  Michael R Witten; Eric N Jacobsen
Journal:  Angew Chem Int Ed Engl       Date:  2014-04-29       Impact factor: 15.336

4.  Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells.

Authors:  A M Latham; A F Bruns; J Kankanala; A P Johnson; C W G Fishwick; S Homer-Vanniasinkam; S Ponnambalam
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Dual catalysis in enantioselective oxidopyrylium-based [5 + 2] cycloadditions.

Authors:  Noah Z Burns; Michael R Witten; Eric N Jacobsen
Journal:  J Am Chem Soc       Date:  2011-08-25       Impact factor: 15.419

6.  In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.

Authors:  Antony M Latham; Jayakanth Kankanala; Gareth W Fearnley; Matthew C Gage; Mark T Kearney; Shervanthi Homer-Vanniasinkam; Stephen B Wheatcroft; Colin W G Fishwick; Sreenivasan Ponnambalam
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.